#United States #Aurora #Pediatric Healthcare #Children's Hospital Colorado #dwarfism treatment

Enhancing Growth Outcomes for Children with Dwarfism

Recent findings from an international study conducted at Children’s Hospital Colorado and the University of Colorado Anschutz School of Medicine have shown remarkable advancements in treating children with achondroplasia, the most prevalent type of dwarfism. This pioneering research emphasizes the commitment of Children’s Colorado to furthering pediatric orthopedic studies and providing innovative therapies for rare skeletal disorders.

Achondroplasia affects roughly 1 in every 26,000 to 40,000 children and is linked to genetic alterations that disrupt normal bone growth and development. This condition can lead to a variety of health complications affecting the spine, limbs, and overall body proportions. Children with achondroplasia often experience significant challenges, including disproportionate heights and potential health complications involving various organs and systems.

Children’s Hospital Colorado is integral to a global trial involving 27 sites across 10 countries that are investigating an oral therapy named infigratinib, under the sponsorship of BridgeBio Pharma. The Phase 3 trial was meticulously designed as a randomized, double-blind, and placebo-controlled study, involving 114 children aged between 3 and under 18 years, who received either the therapy or a placebo over a period of 52 weeks.

The findings indicated substantial growth improvements, as the group receiving the oral treatment exhibited an increase in height of approximately 2.10 centimeters per year compared to those taking the placebo. Moreover, children aged between 3 and 8 showed considerable enhancements in their body proportions, which is a critical developmental stage.

Dr. Klane White, who serves as the Rose Brown Endowed Chair at Children’s Colorado and is a co-author of the study, stated, "While growth was the primary objective of this research, these results open the door for the possibility of therapies that not only aid in physical growth but also contribute positively to the overall health and quality of life for children battling achondroplasia."

The treatment mechanism of infigratinib focuses on addressing the underlying pathophysiology associated with achondroplasia caused by the overactivity of the FGFR3 signaling pathway, which suppresses bone growth. By inhibiting this pathway, the oral therapy promotes enhanced skeletal development among affected children.

Dr. Ronald Sokol, Chief Scientific Officer at Children’s Colorado, emphasized the hospital’s dedication to bettering the lives of children with complex musculoskeletal issues. He noted, “We are thrilled to contribute to global initiatives that aim to expand treatment options for patients and their families.”

Although the results of the study are optimistic, further research is needed to comprehensively understand the long-term effects of this treatment and its implications on the children's overall health and functional abilities. The side effects noted during the trial were generally mild to moderate and resembled those of common childhood ailments, with no severe adverse reactions or fatalities reported. Continuing the journey, participants will enter a longer-term follow-up study to monitor ongoing health impacts.

Children’s Hospital Colorado stands out as a foremost pediatric facility committed to improving child health through a blend of clinical care, research, and community advocacy. Renowned for its multidisciplinary approach, the Orthopedics Institute at Children’s Colorado offfers targeted care for various musculoskeletal disorders including rare skeletal dysplasias.

About Children’s Hospital Colorado

Founded in 1908, Children’s Hospital Colorado is recognized among the nation’s best pediatric health systems, pursuing excellence in child healthcare through a framework of patient support, innovative research, and community outreach. With multiple locations throughout Colorado, including its primary facility at the Anschutz Medical Campus in Aurora, Children's Colorado remains at the forefront of transforming pediatric healthcare worldwide. For further insights about their endeavors, visit www.childrenscolorado.org and connect on social media platforms such as Facebook, Instagram, and YouTube.